<DOC>
	<DOC>NCT02125461</DOC>
	<brief_summary>A Global Study to Assess the Effects of MEDI4736 following concurrent chemoradiation in Patients with Stage III Unresectable Non-Small Cell Lung Cancer.</brief_summary>
	<brief_title>A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>1. Age at least 18 years. 2. Documented evidence of NSCLC (locally advanced, unresectable, Stage III) 3. Patients must have received at least 2 cycles of platinumbased chemotherapy concurrent with radiation therapy. 4. World Health Organisation (WHO) Performance Status of 0 to 1. 5. Estimated life expectancy of more than 12 weeks. 1. Prior exposure to any antiPD1 or antiPDL1 antibody. 2. Active or prior autoimmune disease or history of immunodeficiency. 3. Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV. 4. Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris. 5. Any unresolved toxicity CTCAE &gt;Grade 2 from the prior chemoradiation therapy. 6. Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Locally advanced</keyword>
	<keyword>Unresectable Non-Small Cell Lung Cancer</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>PD-L1</keyword>
	<keyword>Stage III Non-Small Cell Lung Cancer</keyword>
	<keyword>Chemoradiation</keyword>
	<keyword>Immune-mediated cancer therapy</keyword>
</DOC>